Exploiting the Unique T Cell Response to CMV for a Cancer Vaccine
利用 T 细胞对 CMV 的独特反应来开发癌症疫苗
基本信息
- 批准号:7742485
- 负责人:
- 金额:$ 20.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-04-01 至 2011-03-31
- 项目状态:已结题
- 来源:
- 关键词:AdjuvantAntigensAtrophicAttenuatedCD34 geneCD8B1 geneCancer VaccinesCellsCharacteristicsChronicCytomegalovirusCytomegalovirus InfectionsCytomegalovirus VaccinesDendritic CellsDoseEconomic InflationEngineeringEpitopesEventFemaleFibroblastsGene ExpressionGlycoproteinsGoalsHumanImmuneImmune responseImmune systemImmunityImmunizationImmunobiologyImmunologic MemoryImmunologic SurveillanceImmunotherapeutic agentImmunotherapyIn VitroIndividualInfectionInfertilityLifeLigandsMacaca mulattaMeasuresMemoryModelingMonitorMonkeysMusNeoplasm MetastasisNormal tissue morphologyOvarianPatientsPersonal CommunicationPhenotypeProteinsRecombinantsRecurrenceResistanceRouteSelf ToleranceStem cellsT memory cellT-LymphocyteTestingTimeTissuesTreatment ProtocolsTumor AntigensVaccinationVaccinesViralVirusZona Pellucidabaseefficacy testingimmunogenicimmunogenicitylatent infectionmelanomamonolayerperipheral bloodplasmid DNApromoterpublic health relevancerecombinant virusresponsetumorvaccine efficacyvectorvector vaccinevector-based vaccine
项目摘要
DESCRIPTION (provided by applicant): The goal of this project is to develop an attenuated cytomegalovirus-based vaccine vector expressing the melanoma antigen trp-1 for use in tumor immunotherapy. Certain features of the immunobiology of CMV suggest that a vaccine based on it could make a unique contribution to the tumor immunotherapy arsenal. It is extraordinarily immunogenic for CD8 T cells; it has been shown to overcome self-tolerance to a tissue specific antigen, and as a vaccine vector it can be used sequentially. However, a live virus has obvious limitations as a vector for immune-compromised tumor patients. We have recently shown that a CMV vector that is completely replication deficient nevertheless establishes latency and can prime the characteristic ongoing massive immune response. The goal of the current project is to develop the replication deficient MCMV strain as a vaccine vector, using the well characterized B16 mouse melanoma model. The majority of the project is devoted to optimizing the immune response that can be elicited by the replication deficient vector. We will compare immunogenicity when the tumor antigen is expressed behind different viral promoters, and determine whether antigen expression and immunogenicity can be enhanced further by the use of adjuvants that drive viral IE gene expression. We will use two measures of vaccine efficacy (a) size of the CD8 T cell response an (b) ability to protect against tumor challenge using B16 cells.
PUBLIC HEALTH RELEVANCE: Cytomegalovirus (CMV) infection, which is usually asymptomatic and has been safely used as a vaccine, generates a potent cellular immune response and immunological memory that is maintained for life. Previously, CMV has been engineered to induce the immune system to target normal tissues. Our goal is to harness this potent immune response elicited by CMV to test use as an effective tumor vaccine. A safe vaccine vector that is unable to replicate will be generated for this purpose.
描述(由申请人提供):本项目的目标是开发一种表达黑色素瘤抗原trp-1的减毒巨细胞病毒疫苗载体,用于肿瘤免疫治疗。CMV免疫生物学的某些特征表明,基于它的疫苗可以为肿瘤免疫治疗武器库做出独特的贡献。它对CD 8 T细胞具有特别的免疫原性;它已被证明可以克服对组织特异性抗原的自身耐受性,并且作为疫苗载体,它可以顺序使用。然而,活病毒作为免疫受损肿瘤患者的载体具有明显的局限性。我们最近已经表明,CMV载体,是完全复制缺陷,但建立潜伏期,并可以启动的特征正在进行的大规模免疫反应。本项目的目标是使用充分表征的B16小鼠黑色素瘤模型开发复制缺陷MCMV株作为疫苗载体。该项目的大部分致力于优化可由复制缺陷型载体引起的免疫应答。我们将比较当肿瘤抗原在不同病毒启动子后表达时的免疫原性,并确定是否可以通过使用驱动病毒IE基因表达的佐剂进一步增强抗原表达和免疫原性。我们将使用两种疫苗效力的测量方法(a)CD 8 T细胞应答的大小和(B)使用B16细胞保护免受肿瘤攻击的能力。
公共卫生关系:巨细胞病毒(CMV)感染,通常是无症状的,并已被安全地用作疫苗,产生有效的细胞免疫应答和免疫记忆,维持终身。以前,CMV已经被工程化以诱导免疫系统靶向正常组织。我们的目标是利用CMV引起的这种有效的免疫反应来测试作为有效的肿瘤疫苗的用途。将为此目的产生不能复制的安全疫苗载体。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ann B Hill其他文献
Cytomegalovirus containing TRP2 antigen provides protective immunity against the poorly immunogenic B16BL6-D5 melanoma
- DOI:
10.1186/2051-1426-1-s1-p271 - 发表时间:
2013-11-01 - 期刊:
- 影响因子:10.600
- 作者:
Michael Neuberger;Shawn M Jensen;Guangwu Xu;Tameka Smith;Hong-Ming Hu;Ann B Hill;Carlo B Bifulco;Bernard A Fox - 通讯作者:
Bernard A Fox
Ann B Hill的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ann B Hill', 18)}}的其他基金
T cell response to fibroblast-trophic CMV vaccine in humans
人类 T 细胞对成纤维细胞营养型 CMV 疫苗的反应
- 批准号:
8973535 - 财政年份:2014
- 资助金额:
$ 20.17万 - 项目类别:
T cell response to fibroblast-trophic CMV vaccine in humans
人类 T 细胞对成纤维细胞营养型 CMV 疫苗的反应
- 批准号:
8839088 - 财政年份:2014
- 资助金额:
$ 20.17万 - 项目类别:
Cytomegalovirus and diseases of aging: a secondary analysis of NHANES III data
巨细胞病毒与衰老疾病:NHANES III 数据的二次分析
- 批准号:
8247692 - 财政年份:2011
- 资助金额:
$ 20.17万 - 项目类别:
Cytomegalovirus and diseases of aging: a secondary analysis of NHANES III data
巨细胞病毒与衰老疾病:NHANES III 数据的二次分析
- 批准号:
8095593 - 财政年份:2011
- 资助金额:
$ 20.17万 - 项目类别:
Exploiting the Unique T Cell Response to CMV for a Cancer Vaccine
利用 T 细胞对 CMV 的独特反应来开发癌症疫苗
- 批准号:
7796744 - 财政年份:2009
- 资助金额:
$ 20.17万 - 项目类别:
CD8 T Cell Response to Murine Cytomegalovirus
CD8 T 细胞对鼠巨细胞病毒的反应
- 批准号:
8698704 - 财政年份:2002
- 资助金额:
$ 20.17万 - 项目类别:
The CD8 T cell response to murine cytomegalovirus
CD8 T 细胞对鼠巨细胞病毒的反应
- 批准号:
7540954 - 财政年份:2002
- 资助金额:
$ 20.17万 - 项目类别:
MECHANISM OF MCMV's INHIBITION OF ANTIGEN PRESENTATION
MCMV抑制抗原呈递的机制
- 批准号:
7027644 - 财政年份:2002
- 资助金额:
$ 20.17万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 20.17万 - 项目类别:
Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
- 批准号:
10083718 - 财政年份:2023
- 资助金额:
$ 20.17万 - 项目类别:
Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
- 批准号:
480030 - 财政年份:2023
- 资助金额:
$ 20.17万 - 项目类别:
Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
- 批准号:
MR/X009254/1 - 财政年份:2023
- 资助金额:
$ 20.17万 - 项目类别:
Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
- 批准号:
22KJ1758 - 财政年份:2023
- 资助金额:
$ 20.17万 - 项目类别:
Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
- 批准号:
BB/Y000927/1 - 财政年份:2023
- 资助金额:
$ 20.17万 - 项目类别:
Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
- 批准号:
10795212 - 财政年份:2023
- 资助金额:
$ 20.17万 - 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
- 批准号:
23K18249 - 财政年份:2023
- 资助金额:
$ 20.17万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 20.17万 - 项目类别:
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
- 批准号:
10735075 - 财政年份:2023
- 资助金额:
$ 20.17万 - 项目类别: